Concepts (70)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 8 | 2022 | 390 | 1.110 |
Why?
|
| Tamoxifen | 2 | 2012 | 30 | 0.450 |
Why?
|
| Aromatase Inhibitors | 1 | 2012 | 8 | 0.380 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 19 | 0.370 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 26 | 0.330 |
Why?
|
| Postmenopause | 1 | 2010 | 57 | 0.330 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 62 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 240 | 0.300 |
Why?
|
| Dry Eye Syndromes | 1 | 2006 | 1 | 0.250 |
Why?
|
| Cyclosporine | 1 | 2006 | 12 | 0.250 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 53 | 0.240 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 111 | 0.230 |
Why?
|
| Publications | 1 | 2021 | 13 | 0.180 |
Why?
|
| Journal Impact Factor | 1 | 2021 | 13 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 81 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2021 | 51 | 0.170 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 31 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2021 | 307 | 0.160 |
Why?
|
| Female | 9 | 2022 | 12904 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 192 | 0.120 |
Why?
|
| Humans | 9 | 2022 | 22823 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2010 | 1487 | 0.110 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2012 | 10 | 0.090 |
Why?
|
| Ovariectomy | 1 | 2012 | 26 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2012 | 49 | 0.090 |
Why?
|
| Night Blindness | 1 | 2010 | 2 | 0.080 |
Why?
|
| Fenretinide | 1 | 2010 | 5 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 235 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2010 | 373 | 0.080 |
Why?
|
| Radiodermatitis | 1 | 2009 | 2 | 0.080 |
Why?
|
| Taxoids | 1 | 2009 | 11 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2009 | 44 | 0.070 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2008 | 3 | 0.070 |
Why?
|
| Genes, erbB-2 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 41 | 0.070 |
Why?
|
| Middle Aged | 3 | 2010 | 7873 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 4 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Adult | 2 | 2010 | 6896 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 52 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 227 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 1412 | 0.060 |
Why?
|
| Muramidase | 1 | 2006 | 1 | 0.060 |
Why?
|
| Tears | 1 | 2006 | 1 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2006 | 14 | 0.060 |
Why?
|
| Visual Acuity | 1 | 2006 | 36 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 164 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 3717 | 0.050 |
Why?
|
| Breast | 1 | 2022 | 23 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 27 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 1019 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 71 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2022 | 2976 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2006 | 2934 | 0.040 |
Why?
|
| Aged | 1 | 2010 | 7412 | 0.040 |
Why?
|
| United States | 1 | 2022 | 1762 | 0.030 |
Why?
|
| Male | 1 | 2006 | 12400 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2009 | 29 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2008 | 16 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 19 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2008 | 37 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 294 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2008 | 156 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2007 | 26 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 100 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 83 | 0.020 |
Why?
|
| Prognosis | 1 | 2008 | 714 | 0.020 |
Why?
|